Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customised formulation of ranibizumab over time. Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit vascular endothelial growth factor-A (VEGF-A), a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.

In the United States, Susvimo is approved for the treatment of people with the vision-threatening retinal condition neovascular or “wet” age-related macular degeneration who have previously responded to at least two anti-VEGF injections.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.